How farming planted seeds for the Internet - Patricia Russac
View full lesson: http://ed.ted.com/lessons/how-farming-planted-seeds-for-the-internet-patricia-russac What does farming have to do with invention and innova...

By: TEDEducation

Continued here:
How farming planted seeds for the Internet - Patricia Russac - Video

Recommendation and review posted by Bethany Smith

Squats Necessary to Gain Muscle?
Thanks for the support! Please LIKE and COMMENT if you enjoy! #9675; Top 5 Bodybuilding Snacks: http://youtu.be/s0CLtvWk3dc #9675; Six Pack Abs Workout: http://youtu.b...

By: MichaelKoryFitness

See original here:
Squats Necessary to Gain Muscle? - Video

Recommendation and review posted by Bethany Smith

WALTHAM, Mass.--(BUSINESS WIRE)--

Interleukin Genetics, Inc. (ILIU) announced today that it will host a conference call and Webcast on Thursday, March 28, 2013 at 4:30 p.m. (EST) to discuss the Companys fourth quarter and 2012 year end results.

To access the live call, dial 877-324-1976 (domestic) or 631-291-4550 (international). The live Webcast and replay access of the teleconference will be available on the Investors section of Interleukin Genetics, Inc.s Website at http://www.ilgenetics.com.

About Interleukin Genetics

Interleukin Genetics, Inc. (ILIU) develops and markets a line of genetic tests under the Inherent Health and PST brands.The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics flagship products include its proprietary PST genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists, and the Inherent Health Weight Management Genetic Test that identifies the most effective diet and exercise program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, Mass. and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit http://www.ilgenetics.com.

See more here:
Interleukin Genetics , Inc. Announces Conference Call to Discuss Fourth Quarter 2012 Results

Recommendation and review posted by Bethany Smith

PHOENIX--(BUSINESS WIRE)--

Good Start Genetics, Inc.,an innovative molecular diagnostics company which has developed the new gold standard in carrier screening, presented clinical data at this weeks annual meeting of the American College of Medical Genetics and Genomics (ACMG). These data were generated using its unique, next-generation sequencing (NGS) based carrier screening platform in the IVF setting.

In the first of two abstracts presented at ACMG, entitled Carrier Screening of 4,200 IVF Patients Utilizing Next Generation DNA Sequencing Detects Common, Rare and Otherwise Undetectable Mutations Across Several Diseases, the authors report the detection of numerous rare and novel pathogenic (i.e., disease-causing) mutations among 14 diseases in a clinical setting. The authors conclude that without NGS, these carriers would have been missed, putting the IVF couples at increased risk of having a child with one of these genetic disorders.

In the second abstract presented, entitled Next Generation DNA Sequencing Detects Rare and Novel Mutations Across Several Diseases, the authors describe the identification of 50 pathogenic alleles across ten diseases among over 3,300 patient samples screened. In this study, 34% of the mutations identified using Good Starts screening tests would have been missed had traditional tests been used.

These results clearly demonstrate that NGS can detect far more disease-causing mutations than can older screening technologies currently in use in the IVF setting, said Don Hardison, president and CEO of Good Start Genetics. Were very pleased to be able to offer this cutting edge technology to IVF centers across the country, and even more pleased that we are detecting carriers that would have otherwise been missed.

Since its national launch in April 2012, Good Start Genetics high-complexity, CLIA- and CAP-accredited laboratory has processed tens of thousands of test orders. The GoodStart Select carrier screening service detects common pathogenic (i.e., disease-causing) mutations in carriers across all 23 diseases recommended for testing by major medical societies, as well as rare pathogenic mutations that would go undetected by laboratories using older, traditional genotyping-based technologies. For example, most traditional genotyping-based technologies detect about 100 pathogenic mutations for cystic fibrosis (CF), while GoodStart Select detects 550 pathogenic mutations.

About Good Start Genetics, Inc.

Good Start Genetics is setting the new gold standard in carrier screening by making testing for the most comprehensive set of known and novel disease-causing mutations accessible for routine clinical practice. After years of development and rigorous validation, Good Start Genetics has harnessed the power of next-generation sequencing and other best-in-class technologies to provide highly accurate, actionable and affordable tests for all disorders recommended for genetic testing by ACOG and ACMG. For these reasons, fertility specialists and their patients can have a high degree of confidence in their carrier screening results, and no longer have to compromise accuracy for price. For more information, visit http://www.goodstartgenetics.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130321006005/en/

Read more:
Good Start Genetics Reports Clinical Data at the Annual Meeting of the American College of Medical Genetics and ...

Recommendation and review posted by Bethany Smith

Pain Control Clinic scottsdale az | 480-448-1152
http://www.arizonaklaserneuropathycenter.com/ Pain Control Clinic scottsdale az 480-448-1152 Laser Therapy is non-invasive, drug free and painless and there ...

By: PainControlClinic

Read more:
Pain Control Clinic scottsdale az | 480-448-1152 - Video

Recommendation and review posted by Bethany Smith

A clinical trial using a patient's own immune system to produce remissions in adults with acute leukemia could be a major breakthrough in the fight against all different kinds of cancer.

The new study, published Wednesday in the journal Science Translational Medicine, took five patients with untreatable cancer, and using their own immune systems, injected genetic material into the patient's white cells to turn them into cancer fighters. The modified white cells then went out in the body and destroyed all the cancer cells, causing the patients to go into remission, according to the study.

"Cancer cells are similar enough to your normal cells that the T-cells cannot recognize it," Dr. Richard M. Stone, Program Director of the Adult Leukemia Program at the Dana-Farber Cancer Institute, told ABC News. "By injecting genes into these cells, you're educating the immune system to recognize the cancer."

This study only reviewed patients with acute lymphoblastic leukemia. While 80 to 90 percent of children with ALL can be cured with conventional therapy, adult ALL is genetically different and only enjoys a cure rate of roughly 40 percent.

Of the five patients, four had bone marrow transplants after receiving the new treatment. The other patient suffered medical problems that made a transplant impossible, relapsed and died shortly thereafter.

One of the patients, known in the study as Patient 5, is David Aponte, 58, a sound man at ABC News.

Last summer, Aponte underwent a physically and emotionally taxing regimen of chemotherapy. However, while still undergoing treatment, doctors discovered that the disease was back. With few options left, he decided to join the new T-cell study.

Doctors took millions of Aponte's disease-fighting white blood cells, and used a retrovirus to change those cells into targeted cancer fighters. The treatment can cause side effects, including what is known as a "cytokine storm," in which the engineered T-cells become activated, releasing all kinds of proteins that can make the patient ill. For Aponte, this meant a drop in blood pressure, a fever that spiked to 105 degrees and a coma that lasted eight days.

"Down the road if this continues to be developed, one could imagine therapies that would modulate the side effects, slowing down the anti-tumor response," explained Dr. Stone.

Aponte's treatment was successful, and he became one of the patients who successfully went into remission. When he awoke from the coma, not one cancer cell could be found. His leukemia was gone.

More here:
Gene Therapy Could Treat Cancer, Study Finds

Recommendation and review posted by Bethany Smith

A clinical trial using a patient's own immune system to produce remissions in adults with acute leukemia could be a major breakthrough in the fight against all different kinds of cancer.

The new study, published Wednesday in the journal Science Translational Medicine, took five patients with untreatable cancer, and using their own immune systems, injected genetic material into the patient's white cells to turn them into cancer fighters. The modified white cells then went out in the body and destroyed all the cancer cells, causing the patients to go into remission, according to the study.

"Cancer cells are similar enough to your normal cells that the T-cells cannot recognize it," Dr. Richard M. Stone, Program Director of the Adult Leukemia Program at the Dana-Farber Cancer Institute, told ABC News. "By injecting genes into these cells, you're educating the immune system to recognize the cancer."

This study only reviewed patients with acute lymphoblastic leukemia. While 80 to 90 percent of children with ALL can be cured with conventional therapy, adult ALL is genetically different and only enjoys a cure rate of roughly 40 percent.

Of the five patients, four had bone marrow transplants after receiving the new treatment. The other patient suffered medical problems that made a transplant impossible, relapsed and died shortly thereafter.

One of the patients, known in the study as Patient 5, is David Aponte, 58, a sound man at ABC News.

Sciepro/Science Photo Library/Corbis

Last summer, Aponte underwent a physically and emotionally taxing regimen of chemotherapy. However, while still undergoing treatment, doctors discovered that the disease was back. With few options left, he decided to join the new T-cell study.

Doctors took millions of Aponte's disease-fighting white blood cells, and used a retrovirus to change those cells into targeted cancer fighters. The treatment can cause side effects, including what is known as a "cytokine storm," in which the engineered T-cells become activated, releasing all kinds of proteins that can make the patient ill. For Aponte, this meant a drop in blood pressure, a fever that spiked to 105 degrees and a coma that lasted eight days.

"Down the road if this continues to be developed, one could imagine therapies that would modulate the side effects, slowing down the anti-tumor response," explained Dr. Stone.

See original here:
Gene Therapy Could Treat Cancer

Recommendation and review posted by Bethany Smith

Topics: babies, dna, ivf

THE possibility that babies could be born with the DNA of three different people is a step closer, after a consultation showed that most Britons would be happy to see the law changed to allow a radical form of gene therapy.

The IVF therapy would help women in danger of passing on mitochondrial disease to their babies - a potentially fatal metabolic disorder.

An exhaustive survey of public attitudes to the replacement of an affected mother's mitochondria - the tiny "power packs" of cells - with those from an egg donor has found widespread support for the technique.

>>More Lifestyle News

"We've found that there is broad support for permitting mitochondria replacement to give families at risk of mitochondrial disease the chance of having a healthy child," said Professor Lisa Jardine, the chair of the Human Fertilisation and Embryology Authority (HFEA).

"Although some people have concerns about the safety of these techniques, we found that they trust the experts and the regulator to know when it is appropriate to make them available."

But David King, director of Human Genetics Alert, criticised the HFEA for ignoring the potential risks associated with the technique, which has had only limited testing on laboratory animals and is not medically practised anywhere in the world.

"These techniques go far beyond anything existing in both invasiveness to the embryo and complexity, so it's not surprising they pose serious health risks to the child - risks that the HFEA refuses properly to address," Dr King said.

Mitochondrial replacement involves fusing the egg-cell nucleus of the affected mother with an egg cell from an unaffected donor.

Excerpt from:
Public supports gene therapy on IVF embryos

Recommendation and review posted by Bethany Smith

Dr Alok Sharma Stem Cell Therapy Treatment for Stroke
Dr Alok Sharma Stem Cell Therapy Treatment for Stroke before and after compareson After Stem Cell Therapy 1) Can walk almost 50-60 steps at a time without ex...

By: neurogenbsi

Read more here:
Dr Alok Sharma Stem Cell Therapy Treatment for Stroke - Video

Recommendation and review posted by Bethany Smith

The Department of Health (DOH) has restricted hospitals and other facilities from using genetically-altered cells and tissues of human in carrying out stem-cell therapy and treatments in the country. Health secretary Enrique Ona added that their department also prohibits the use of umbilical cord, fat-derived human stem cells, and live animal stem cells for the conduct of the procedure locally.

Related story: Foundation seeks to help people on the verge of suicide On Wednesday, DOH released Administrative Order (AO) 2013-0012 which seeks to ensure the safety of people who want to undergo human stem cell and cell-based therapies.

The AO also prohibits for human treatment and research the creation of human embryos and their derivatives, the use of aborted human fetal stem cells and their derivatives, and plant parts labeled as stem cells, the order stated. Ona hopes AO will make effective and ethical stem cell modalities and practices that will be at par with emerging international and global standards on the very complex nature of this therapy.

Also read: Genetically modified crops threaten organic agriculture He explained the AO also hopes to prevent the introduction, transmission, and spread of communicable diseases by ensuring a minimum quality of service and staff qualification rendered by hospitals and other health facilities capable of utilizing human stem cell preparations and cell-based therapies. These guidelines will classify which stem cell preparations and therapies will be registered and allowed with certain restrictions, Ona said in a statement. Preparations that will be allowed include those with adult human stem cells, human umbilical cord stem cells, and human organ-specific cells, he noted.

Related story: Fresh food make up most of Pinoys' shopping basket, says study He explained that health facilities utilizing stem cell preparations and cell-based or cellular therapies will be mandated to comply with the guidelines set by DOHs Bioethics Advisory Board. The Borad, Ona notes, will ensure that ethical and professional standards are upheld and that contentious scientific, ethical and legal issues are addressed. He said charges and complaints shall be addressed to the DOH Bureau of Health Facilities & Services and the Philippine Food and Drug Agency. Stem cell therapy and treatments are medical procedures where doctors replace malignant cells with healthier cells in an effort to cure or address ailments like cancer. Some facilities also use the procedure for cosmetic purposes, targeting components of the skin like collagen to make patients look younger and healthy.

More here:
DOH restricts hospitals amid stem- cell therapy craze

Recommendation and review posted by Bethany Smith

Lerners Dr. Mendell Presentation - PART 1
lerners Dr. Mendell Presentation - PART 1.

By: JessesJourney

The rest is here:
Lerners Dr. Mendell Presentation - PART 1 - Video

Recommendation and review posted by Bethany Smith

Lerners Dr. Mendell Presentation - PART 2
Lerners Dr. Mendell Presentation - PART 2.

By: JessesJourney

Read the original post:
Lerners Dr. Mendell Presentation - PART 2 - Video

Recommendation and review posted by Bethany Smith

laura en la gene.3gp
Watch Later Miranda Lambert CoversLaura Pacanin Gene Guerciaby vanagangstanigg94 210 views middot; 409. Watch Later Benny Carter Trio at Carnegie Hall Lauraby 60otaku4 1385 views middot; 305. Watch Later Como pez en el agua la arrolladora banda el limon mas adelanteby siddreams 3516271 views middot; 118. Watch Later Dr Laura Niklason on the importance of her AFAR grants for telomerase gene therapy researchby afar1981 1408 views. Loading more suggestions. Load more suggestions. youtube home ...

By: dinlaur

Here is the original post:
laura en la gene.3gp - Video

Recommendation and review posted by Bethany Smith

Motivation for Drug Delivery Research - Luke Theogarajan
Ramsey Majzoub explains Gene Therapy Research conducted in the Safinya Group at UCSBby jennylei8 No views; 251. Watch Later Microjetsby jennylei8 11 views; 5814. Watch Later Bionic and Bioionic Neural Interfacesby UWTV 2392 views; 115. Watch Later Soda Bottle Rocket Launch Trial 3by jennylei8 83 views; 5745. Watch Later bioengineering Insights 2009 biomaterials Part 1by uctelevision 1728 views; 102. Watch Later Soda Bottle Rocket Launch Trial 1by jennylei8 17 views; 718. Watch Later ...

By: jennylei8

See original here:
Motivation for Drug Delivery Research - Luke Theogarajan - Video

Recommendation and review posted by Bethany Smith

ME 141A Final Project - Safinya
ME 141A Final Project - Safinya.

By: jennylei8

Read more from the original source:
ME 141A Final Project - Safinya - Video

Recommendation and review posted by Bethany Smith

Microjets
Microjets.

By: jennylei8

Read the original post:
Microjets - Video

Recommendation and review posted by Bethany Smith

Scarlett and Gene
Christmas Eve eve eve eve 2012.

By: simonkeithpainting

Read more here:
Scarlett and Gene - Video

Recommendation and review posted by Bethany Smith

157
giggles, bored just having fun.....

By: Katherine Johnson

Excerpt from:
157 - Video

Recommendation and review posted by Bethany Smith

Diagnosing Glaucoma - Dr. Dana M. Blumberg
Dana M. Blumberg, M.D., an attending ophthalmologist and Glaucoma specialist at NewYork-Presbyterian/Columbia University Medical Center discusses what Glauco...

By: newyorkpresbyterian

Continued here:
Diagnosing Glaucoma - Dr. Dana M. Blumberg - Video

Recommendation and review posted by Bethany Smith

Eye Care and Beyond - Dr. Dana M. Blumberg
Dana M. Blumberg, M.D., an attending ophthalmologist and Glaucoma specialist at NewYork-Presbyterian/Columbia University Medical Center discusses the dedicat...

By: newyorkpresbyterian

Read the rest here:
Eye Care and Beyond - Dr. Dana M. Blumberg - Video

Recommendation and review posted by Bethany Smith

Most Rewarding Part of Working in Eye Care - Dr. Bryan J. Winn
Bryan J. Winn, M.D., Residency Program Director, Department of Ophthalmology, at NewYork-Presbyterian/Columbia University Medical Center discusses the most r...

By: newyorkpresbyterian

The rest is here:
Most Rewarding Part of Working in Eye Care - Dr. Bryan J. Winn - Video

Recommendation and review posted by Bethany Smith

Ophthalmology Residency Research - Dr. Bryan J. Winn
Dr. Bryan J. Winn, M.D., Residency Program Director, Department of Ophthalmology, at NewYork-Presbyterian/Columbia University Medical Center discusses the br...

By: newyorkpresbyterian

See the article here:
Ophthalmology Residency Research - Dr. Bryan J. Winn - Video

Recommendation and review posted by Bethany Smith

Ophthalmology Residency Training - Dr. Bryan J. Winn
Bryan J. Winn, M.D., Residency Program Director, Department of Ophthalmology, at NewYork-Presbyterian/Columbia University Medical Center discusses the next g...

By: newyorkpresbyterian

Continued here:
Ophthalmology Residency Training - Dr. Bryan J. Winn - Video

Recommendation and review posted by Bethany Smith

Ophthalmology Researchers Clinicians Working Together - Katherine Wert, M.S.
Katherine Wert, Ph.D. Candidate at the Columbia University College of Physicians and Surgeons, discusses the collaborative approach to research at NewYork-Pr...

By: newyorkpresbyterian

See original here:
Ophthalmology Researchers

Recommendation and review posted by Bethany Smith

Harvard Researchers Look at Obesity Gene
No more blaming genetics if you #39;re overweight: researchers found ways that people can cut the effect of #39;the obesity gene #39; in half.

By: FOX47News

Read more:
Harvard Researchers Look at Obesity Gene - Video

Recommendation and review posted by Bethany Smith